Core Insights - NeOnc Technologies Holdings, Inc. reported financial results for Q2 2025, highlighting significant operational achievements and upcoming milestones in their clinical pipeline [1][4]. Clinical Pipeline Progress - NEO100-01, an intranasal therapy for malignant gliomas, and NEO212, a bio-conjugated therapy for brain cancer, are advancing with the final patient cohort in Phase I expected to complete dosing in 2025 [3]. - A pediatric indication trial, NEO100-3, has been initiated with patient recruitment currently underway [3]. Financial Results for Q2 2025 - General and administrative (G&A) expenses increased to $984K from $290K in Q2 2024, attributed to expanded marketing, rent, travel, and costs related to the Middle East partnership [7]. - Research and development (R&D) expenses rose to $677K from $394K in Q2 2024, driven by additional trial sites and increased recruitment efforts [7]. - The net loss for the quarter was $5.68 million, or $0.30 per diluted share, compared to a net loss of $4.52 million, or $0.27 per diluted share in Q2 2024 [7]. Strategic Developments - A $50 million strategic partnership with Quazar Investment has been secured, which will enhance NeOnc's clinical trials platform in the GCC & MENA regions [6]. - The company received $2.5 million in STTR grants from NIH to support the advancement of NEO212 for gliomas and leukemia [6]. - NeOnc has signed an agreement to acquire an AI, 3D bioprinting, and quantum modeling intellectual property portfolio [6]. - The company has been included in the Russell Microcap Index, increasing visibility among institutional investors [6]. Upcoming Catalysts - Full enrollment for the NEO100-01 Phase 2a trial is expected by September 2025, with top-line data readout anticipated in early 2026 [10]. - Completion of the NEO212 Phase I final cohort dosing is also expected in 2025 [10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 801-42567 NEONC TECHNOLOGIES HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 95-1954 ...

Core Insights - NeOnc Technologies Holdings, Inc. has officially incorporated NuroMENA Holdings Ltd. in Abu Dhabi, completing a $50 million cornerstone investment led by Quazar Investment [3][4][6] - This partnership aims to launch NeOnc's CNS platform in the MENA region and accelerate the development of its therapeutic pipeline, including NEO212 and NEO100 programs [4][5] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on therapies for CNS cancers, with a strong intellectual property portfolio and academic collaborations [7] - Quazar Investment is a strategic investment firm managing over $3.3 billion in assets, focusing on transformative investments in biotechnology and healthcare across the MENA region [8] Strategic Partnership - The incorporation of NuroMENA is seen as a significant validation of NeOnc's global vision and commitment to delivering innovative therapies [5] - Quazar Investment will have majority control of NuroMENA, facilitating joint governance and strategic alignment to enhance CNS therapies in the region [6][7]

Core Insights - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, recently featured in a podcast discussing its innovative approaches and market achievements [1][2]. Company Overview - NeOnc Technologies is advancing transformative treatments for brain cancer through its NEO drug development platform, which includes novel drug candidates and delivery methods with patent protections extending to 2038 [2]. - The company has two therapeutics, NEO100 and NEO212, currently in Phase II human clinical trials, both under FDA Fast-Track and Investigational New Drug (IND) status [2]. - NeOnc has secured a $50 million partnership in the Middle East and successfully joined the Russell Microcap Index shortly after its IPO, indicating strong market interest and investor confidence [1]. Technological Focus - The company specializes in intranasal drug delivery methods aimed at overcoming the blood-brain barrier, a significant challenge in treating central nervous system conditions [2]. - NeOnc's partnership with USC's medical school enhances its research capabilities and clinical trial reach, further solidifying its position in the biotech industry [1]. Industry Context - The podcast discussion highlighted the potential impact of AI and quantum computing on the biotech sector, suggesting that these technologies could revolutionize drug development and treatment methodologies [1].

Core Insights - NeOnc Technologies Holdings, Inc. has signed a definitive Letter of Intent to acquire a Delaware entity co-owned by Dr. Ishwar K. Puri and Beth R. Levinson, focusing on innovative treatments for brain cancers [1] - The transaction is valued at $3.5 million, consisting of $500,000 in cash and $3 million in NeOnc common stock priced at $25 per share [2] - Dr. Ishwar K. Puri will join NeOnc's Board of Directors, bringing extensive experience in research and innovation from his role at the University of Southern California [3][4] Company Overview - NeOnc Technologies is a clinical-stage life sciences company dedicated to developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [5] - The company's NEO™ drug development platform has produced novel drug candidates with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II clinical trials [5]

Company Overview - NeOnc Technologies (NTHI) went public despite a tough market and joined the Russell Microcap Index shortly after its IPO [1] - NeOnc Technologies secured a $50 million partnership in the Middle East [1] - The company focuses on intranasal drug delivery for brain cancer and has a partnership with USC's medical school [1] Clinical Trials and Global Reach - NeOnc Technologies is expanding its reach through global clinical trials [1] Industry Trends - AI and quantum computing could transform the biotech industry [1] Podcast Information - Trader Talk on Yahoo Finance delivers expert analysis and actionable insights on market volatility [1] - The podcast is for informational and educational purposes only and should not be construed as investment advice [1]

Core Insights - NeOnc Technologies Holdings, Inc. has signed a definitive agreement for a $50 million strategic partnership with Quazar Investment, aimed at advancing treatments for brain and central nervous system cancers [2][3][4] Company Overview - NeOnc is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system cancers, utilizing its proprietary NEO™ drug development platform [6] - The company has a portfolio of novel drug candidates, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and Investigational New Drug status [6] Strategic Partnership Details - The agreement includes Quazar acquiring 1.4 million shares of NeOnc at $25 per share, totaling $35 million, with an additional $15 million allocated for Phase 2B clinical trials and infrastructure development in the UAE and MENA region [4] - Quazar plans to lead a capital formation round of up to $50 million, with 70% of proceeds directed towards acquiring NeOnc common stock and 30% for clinical trials and infrastructure [4] Future Plans and Conditions - NeOnc must fulfill certain conditions within 120 days, including the legal formation of NuroMENA and NuroCure in Abu Dhabi, for the transaction to be completed [5]

Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [2] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates and delivery methods, with patent protections extending to 2038 [2] - NeOnc's proprietary chemotherapy agents have shown positive effects in laboratory tests and clinical trials, particularly for malignant gliomas [2] Current Developments - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [2] - The company has an exclusive worldwide patent portfolio licensed from the University of Southern California, covering multiple uses for NEO100, NEO212, and other products [2] Upcoming Events - Management will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025, providing an opportunity for investors to schedule one-on-one meetings [1]

Core Points - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [1][4] - The company will have its Executive Chairman, Amir Heshmatpour, featured in a live interview on July 24, 2025, at 11:00 a.m. ET [1] - NeOnc has executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment [2] - The company has been included in the Russell Microcap Index, which is part of its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is dedicated to developing and commercializing therapeutics that address challenges in overcoming the blood-brain barrier [4] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [4] - NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [4]

Core Insights - NeOnc Technologies Holdings, Inc. is advancing transformative treatments for brain and central nervous system cancers and is featured in a live interview with financial commentator Kenny Polcari [1][4] - The company executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment, aimed at expanding its market presence in the UAE and broader GCC and MENA regions [2] - NeOnc was included in the Russell Microcap Index, which aligns with its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is a clinical-stage life sciences company focused on developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [4] - The company's NEO™ drug development platform has produced novel drug candidates with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and IND status [4]